Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal amphotericin B for HIV-negative talaromycosis (observational cohort)
ChiCTR2400084718Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- May 2024
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of liposomal amphotericin b in talaromycosis, sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Clinical response rate at day 14 after treatment. Planned start May 2024; status: not yet recruiting.
02
Drugs
liposomal amphotericin b
03
Conditions
talaromycosis
Beyond the preview
Go deeper on ChiCTR2400084718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084718.